Provided by Tiger Trade Technology Pte. Ltd.

ABBISKO-B

13.670
+0.1200.89%
Volume:1.50M
Turnover:20.15M
Market Cap:9.21B
PE:134.69
High:13.710
Open:13.550
Low:13.150
Close:13.550
52wk High:19.780
52wk Low:6.560
Shares:674.00M
HK Float Shares:674.00M
Volume Ratio:1.10
T/O Rate:0.22%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.101
ROE:2.85%
ROA:0.78%
PB:4.18
PE(LYR):134.69
PS:13.12

Loading ...

Abbisko Cayman Ltd - FDA Grants Fast Track Designation to Abbisko's Irpagratinib

THOMSON REUTERS
·
Feb 10

Abbisko Cayman (02256) Announces Monthly Return for January 2026

Bulletin Express
·
Feb 05

Assessing Abbisko Cayman (SEHK:2256) Valuation After FDA Acceptance Of Pimicotinib NDA

Simply Wall St.
·
Jan 22

Zhongtai Securities Maintains "Buy" Rating on ABBISKO-B (02256), Notes Progress of ABSK021 Towards Approval in China and US

Stock News
·
Jan 16

BRIEF-Abbisko Cayman's New Drug Application For Pimicotinib Formally Accepted By U.S. FDA

Reuters
·
Jan 13

Abbisko Tumor Treatment Pimicotinib Accepted for U.S. Review

MT Newswires Live
·
Jan 13

ABBISKO-B (02256) Announces FDA Acceptance of Bejema® NDA for TGCT Treatment

Stock News
·
Jan 13

Abbisko Cayman - Unit's New Drug Application for Colony-Stimulating Factor 1 Receptor Inhibitor Pimicotinib Formally Accepted by US FDA

THOMSON REUTERS
·
Jan 13

Abbisko Therapeutics Secures FDA Acceptance for Pimicotinib NDA

Reuters
·
Jan 13

Major Breakthrough: Abbisko-B's (02256) Tenosynovial Giant Cell Tumor Drug Bejema® NDA Accepted by FDA

Stock News
·
Jan 13

FDA Accepts Abbisko Cayman NDA for Pimicotinib in Tenosynovial Giant Cell Tumor

Reuters
·
Jan 13

Abbisko Therapeutics Announces FDA Acceptance of the Nda for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

THOMSON REUTERS
·
Jan 13

Shenwan Hongyuan Maintains "Buy" Rating on ABBISKO-B (02256) as First Self-Developed Drug Approved for Market

Stock News
·
Dec 29, 2025

Abbisko Unit Gets China Investigational New Drug Clearance for Tumor Drug

MT Newswires Live
·
Dec 24, 2025

CICC Maintains Outperform Rating on ABBISKO-B (02256) with Target Price of HK$20

Stock News
·
Dec 24, 2025

BRIEF-Abbisko Cayman Says NMPA Clears IND Application For Unit's Abbisko's Absk141

Reuters
·
Dec 24, 2025

ABBISKO-B (02256): NMPA Approves IND for Oral Small Molecule KRAS G12D Inhibitor ABSK141

Stock News
·
Dec 24, 2025

Abbisko Cayman Ltd - Nmpa Clears Ind Application for Unit's Abbisko's Absk141

THOMSON REUTERS
·
Dec 24, 2025

Abbisko Cayman Ltd. Wins NMPA IND Clearance for KRAS G12D Inhibitor ABSK141

Reuters
·
Dec 24, 2025

ABBISKO-B (02256): Pimicotinib Approval Accelerates Value Realization of "Billion-Dollar Molecule"

Stock News
·
Dec 23, 2025